THE ANSWER:
OUR SOURCES:
Dr. David Putrino, Director of Rehabilitation Innovation at Mount Sinai Health System
Dr. Greg Vanichkachorn, Division of Preventive, Occupational, and Aerospace Medicine at Mayo Clinic
Dr. Tae Chung, Assistant Professor of Physical Medicine and Rehabilitation at Johns Hopkins Medicine
Michaelene Carlton, a long-hauler COVID patient
Keri Kae Gebo, a long-hauler COVID patient
HOW WE GOT THERE:
“My everyday life has completely changed,” Carlton said.
When she contracted the virus last March, her symptoms were mild. A month later, her health suddenly declined.
The 47-year-old is still out of work on disability, with daily headaches and extreme fatigue. Her heart races when she stands up. Once an avid runner, she now struggles to get off the couch. She can’t do much with her family, and only leaves home for appointments with her doctors.
How long do covid side effects last? Long term effects fact check wusa9.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wusa9.com Daily Mail and Mail on Sunday newspapers.
Nanotech Jumps Blood-Brain Barrier To Kill Cancer in Mice
A new synthetic protein nanoparticle capable of slipping past the nearly impermeable blood-brain barrier in mice could deliver cancer-killing drugs directly to malignant brain tumors, new research shows.
The study is the first to demonstrate an intravenous medication that can cross the blood-brain barrier.
I’ve worked in this field for more than 10 years and have not seen anything like this.
The discovery could one day allow new clinical therapies for treating glioblastoma, the most common and aggressive form of brain cancer in adults, and one whose incidence is rising in many countries. Today’s median survival for patients with glioblastoma is around 18 months; the average 5-year survival rate is below 5%.
Close
The National Institutes of Health researchers have recently isolated a set of potential and tiny antibodies, also called nanobodies as shields from SARS-CoV-2, reportedly produced by a llama Cormac.
Initial findings published in Scientific Reports suggest that at least one of the said nanobodies, also known as NIH-CoVnb-112, could prevent infections and identify virus particles by grabbing hold of SARS-CoV-2 spike proteins.
Additionally, the nanobody seemed effective equally well in either aerosol or liquid form, suggesting it could stay effective following inhalation. SARS-CoV-2 is a virus that causes COVID-19.
The research, led by two neuroscientists, Thomas J. or TJ Esparza, BS, and David Brody, MD, Ph.D., is working in a brain imaging laboratory at the National Institute of Neurological Disorders Stroke or NIND of the NIH.